tbuckley/cabot-search huggingface dataset:
Travel-Time Disparities in Access to Proton Beam Therapy for Cancer Treatment
Authors: Todd Burus, Alexander D. VanHelene, Michael K. Rooney, Krystle A. Lang Kuhs, W. Jay Christian, Christopher McNair, Sanjay Mishra, Arnold C. Paulino, Grace L. Smith, Steven J. Frank, Jeremy L. Warner
Journal: JAMA Network Open (2024)

Importance Proton beam therapy is an emerging radiotherapy treatment for patients with cancer that may produce similar outcomes as traditional photon-based therapy for many cancers while delivering lower amounts of toxic radiation to surrounding tissue. Geographic proximity to a proton facility is a critical component of ensuring equitable access both for indicated diagnoses and ongoing clinical trials. Objective To characterize the distribution of proton facilities in the US, quantify drive-time access for the population, and investigate the likelihood of long commutes for certain population subgroups. Design, Setting, and Participants This population-based cross-sectional study analyzed travel times to proton facilities in the US. Census tract variables in the contiguous US were measured between January 1, 2017, and December 31, 2021. Statistical analysis was performed from September to November 2023. Exposures Drive time in minutes to nearest proton facility. Population totals and prevalence of specific factors measured from the American Community Survey: age; race and ethnicity; insurance, disability, and income status; vehicle availability; broadband access; and urbanicity. Main Outcomes and Measures Poor access to proton facilities was defined as having a drive-time commute of at least 4 hours to the nearest location. Median drive time and percentage of population with poor access were calculated for the entire population and by population subgroups. Univariable and multivariable odds of poor access were also calculated for certain population subgroups. Results Geographic access was considered for 327 536 032 residents of the contiguous US (60 594 624 [18.5%] Hispanic, 17 974 186 [5.5%] non-Hispanic Asian, 40 146 994 [12.3%] non-Hispanic Black, and 195 265 639 [59.6%] non-Hispanic White; 282 031 819 [86.1%] resided in urban counties). The median (IQR) drive time to the nearest proton facility was 96.1 (39.6-195.3) minutes; 119.8 million US residents (36.6%) lived within a 1-hour drive of the nearest proton facility, and 53.6 million (16.4%) required a commute of at least 4 hours. Persons identifying as non-Hispanic White had the longest median (IQR) commute time at 109.8 (48.0-197.6) minutes. Multivariable analysis identified rurality (odds ratio [OR], 2.45 [95% CI, 2.27-2.64]), age 65 years or older (OR, 1.09 [95% CI, 1.06-1.11]), and living below the federal poverty line (OR, 1.22 [1.20-1.25]) as factors associated with commute times of at least 4 hours. Conclusions and Relevance This cross-sectional study of drive-time access to proton beam therapy found that disparities in access existed among certain populations in the US. These results suggest that such disparities present a barrier to an emerging technology in cancer treatment and inhibit equitable access to ongoing clinical trials.
Infant Behaviors, Prenatal Cocaine Exposure, and Adult Intelligence
Authors: Lynn T. Singer, Jeffrey M. Albert, Sonia Minnes, Meeyoung O. Min, June-Yung Kim
Journal: JAMA Network Open (2024)

Importance Linking prenatal drug exposures to both infant behavior and adult cognitive outcomes may improve early interventions. Objective To assess whether neonatal physical, neurobehavioral, and infant cognitive measures mediate the association between prenatal cocaine exposure (PCE) and adult perceptual reasoning IQ. Design, Setting, and Participants This study used data from a longitudinal, prospective birth cohort study with follow-up from 1994 to 2018 until offspring were 21 years post partum. A total of 384 (196 PCE and 188 not exposed to cocaine [NCE]) infants and mothers were screened for cocaine or polydrug use. Structural equation modeling was performed from June to November 2023. Exposures Prenatal exposures to cocaine, alcohol, marijuana, and tobacco assessed through urine and meconium analyses and maternal self-report. Main Outcomes and Measures Head circumference, neurobehavioral assessment, Bayley Scales of Infant Development, Fagan Test of Infant Intelligence score, Wechsler Perceptual Reasoning IQ, Home Observation for Measurement of the Environment (HOME) score, and blood lead level. Results Among the 384 mothers in the study, the mean (SD) age at delivery was 27.7 (5.3) years (range, 18-41 years), 375 of 383 received public assistance (97.9%) and 336 were unmarried (87.5%). Birth head circumference (standardized estimate for specific path association, −0.05, SE = 0.02; P = .02) and 1-year Bayley Mental Development Index (MDI) (standardized estimate for total of the specific path association, −0.05, SE = 0.02; P = .03) mediated the association of PCE with Wechsler Perceptual Reasoning IQ, controlling for HOME score and other substance exposures. Abnormal results on the neurobehavioral assessment were associated with birth head circumference (β = −0.20, SE = 0.08; P = .01). Bayley Psychomotor Index (β = 0.39, SE = 0.05; P &amp;amp;lt; .001) and Fagan Test of Infant Intelligence score (β = 0.16, SE = 0.06; P = .01) at 6.5 months correlated with MDI at 12 months. Conclusions and Relevance In this cohort study, a negative association of PCE with adult perceptual reasoning IQ was mediated by early physical and behavioral differences, after controlling for other drug and environmental factors. Development of infant behavioral assessments to identify sequelae of prenatal teratogens early in life may improve long-term outcomes and public health awareness.
Racial, Ethnic, and Geographic Differences in Vaginal Birth After Cesarean Delivery in the US, 2011-2021
Authors: Rana F. Chehab, Assiamira Ferrara, William A. Grobman, Mara B. Greenberg, Amanda L. Ngo, Emily Z. Wang, Yeyi Zhu
Journal: JAMA Network Open (2024)

This cross-sectional study examines racial, ethnic, and geographic differences in vaginal birth after cesarean delivery in the US, from 2011 to 2021.
Use of Electronic Nicotine Delivery Systems and Age of Asthma Onset Among US Adults and Youths
Authors: Adriana Pérez, Sarah Valencia, Pushan P. Jani, Melissa B. Harrell
Journal: JAMA Network Open (2024)

Importance The association of use of electronic nicotine delivery systems (ENDS) with the age of asthma onset is unknown. Objective To explore the association of past 30-day ENDS use with the age of asthma onset in adults and youths who did not have asthma or chronic obstructive pulmonary disease and never used cigarettes. Design, Setting, and Participants This cohort study was a secondary analysis of waves 1 to 6 of the US nationally representative Population of Tobacco and Health Study (2013-2021). Eligible participants included adults (≥18 years) and youths (12-17 years) who did not have asthma or chronic obstructive pulmonary disease at the first wave of participation. Data analysis was conducted from September 2022 to April 2024. Exposure Past 30-day ENDS use at the first wave of participation in the study preceding the onset of asthma. Main outcome and measures Lower and upper age limits were estimated using the age reported at the first wave of participation and the number of weeks between follow-up waves until asthma was first reported or censored. The association of past 30-day ENDS use with the age of asthma onset was estimated using weighted interval-censoring Cox regression. The cumulative hazard function for the age of asthma onset was estimated using interval-censoring survival analysis. Results A total of 24 789 participants were included, with 7766 adults (4461 female [weighted percentage, 59.11%] and 3305 male [weighted percentage, 40.89%]), representing 80.0 million adults, and 17 023 youths (8514 female [weighted percentage, 50.60%] and 8496 male [weighted percentage 49.32%]), representing 33.9 million youths. By age 27 years, 6.2 per 1000 adults reported asthma incidence (hazard ratio [HR], 0.62%; 95% CI, 0.46%-0.75%). While controlling for covariates, there was a 252% increased risk of the onset of asthma at earlier ages for adults who used ENDS in the past 30 days vs adults who did not (adjusted HR, 3.52; 95% CI, 1.24-10.02). For youths, there was no association of ENDS use in the past 30 days with age of asthma onset (adjusted HR, 1.79; 95% CI, 0.67-4.77), which could be due to a lack of statistical power. Conclusion and relevance In this cohort study, past 30-day ENDS use among adults was associated with earlier ages of asthma onset. These findings suggest that prevention and cessation programs directed to adults who use ENDS are needed to educate the public, protect public health, prevent adverse health outcomes, and motivate users to stop. Furthermore, modifying symptom-screening asthma guidelines, resulting in earlier asthma detection and treatment, may reduce morbidity and mortality due to asthma.
Dynamic Projection of Medication Nonpersistence and Nonadherence Among Patients With Early Breast Cancer
Authors: Pierre Rinder, Théo Marcille, Paul Sinel-Boucher, Mallory Cals-Maurette, Dorra Kanoun, Christelle Levy, Luis Teixeira, Pierre Hornus, Daniel Szeftel, Pierre-Etienne Heudel
Journal: JAMA Network Open (2024)

Importance Oral endocrine treatments have been shown to be effective when carefully adhered to. However, in patients with early breast cancer, adherence challenges are notable, with 17% experiencing nonpersistence and 41% nonadherence at least once. Objective To model the persistence of and adherence to oral anticancer treatment of a patient with localized breast cancer. Design, Setting, and Participants This cohort study was conducted using anonymous reimbursement data belonging to French female patients with breast cancer, extracted from the French Health Insurance database from January 2013 to December 2018. Data analysis was conducted from January 2021 to May 2022. Main Outcomes and Measures The main outcome was the detection of episodes of nonpersistence and nonadherence 6 months before they happened. Adherence was defined as the ratio between the time covered by a drug purchase and the time between 2 purchases; patients were considered nonadherent if the ratio of their next 3 purchases was less than 80%. Disparities in persistence and adherence based on criteria such as age, treatment type, and income were identified. Results A total of 229 695 female patients (median [IQR] age, 63 [52-72] years) with localized breast cancer were included. A deep learning model based on a gated-recurrent unit architecture was used to detect episodes of nonpersistence or nonadherence. This model demonstrated an area under the receiving operating curve of 0.71 for persistence and 0.73 for adherence. Analyzing the Shapley Additive Explanations values also gave insights into the contribution of the different features over the model’s decision. Patients older than 70 years, with past nonadherence, taking more than 1 treatment in the previous 3 months, and with low income had greater risk of episodes of nonpersistence. Age and past nonadherence, including regularity of past adherence, were also important features in the nonadherence model. Conclusions and Relevance This cohort study found associations of patient age and past adherence with nonpersistence or nonadherence. It also suggested that regular intervals in treatment purchases enhanced adherence, in contrast to irregular purchasing patterns. This research offers valuable tools for improving persistence of and adherence to oral anticancer treatment among patients with early breast cancer.
Long-Term Outcomes Associated With β-Lactam Allergies
Authors: Matthew P. Gray, John A. Kellum, Levent Kirisci, Richard D. Boyce, Sandra L. Kane-Gill
Journal: JAMA Network Open (2024)

Importance β-lactam (BL) allergies are the most common drug allergy worldwide, but most are reported in error. BL allergies are also well-established risk factors for adverse drug events and antibiotic-resistant infections during inpatient health care encounters, but the understanding of the long-term outcomes of patients with BL allergies remains limited. Objective To evaluate the long-term clinical outcomes of patients with BL allergies. Design, Setting, and Participants This longitudinal retrospective cohort study was conducted at a single regional health care system in western Pennsylvania. Electronic health records were analyzed for patients who had an index encounter with a diagnosis of sepsis, pneumonia, or urinary tract infection between 2007 and 2008. Patients were followed-up until death or the end of 2018. Data analysis was performed from January 2022 to January 2024. Exposure The presence of any BL class antibiotic in the allergy section of a patient’s electronic health record, evaluated at the earliest occurring observed health care encounter. Main Outcomes and Measures The primary outcome was all-cause mortality, derived from the Social Security Death Index. Secondary outcomes were defined using laboratory and microbiology results and included infection with methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile , or vancomycin-resistant Enterococcus (VRE) and severity and occurrence of acute kidney injury (AKI). Generalized estimating equations with a patient-level panel variable and time exposure offset were used to evaluate the odds of occurrence of each outcome between allergy groups. Results A total of 20 092 patients (mean [SD] age, 62.9 [19.7] years; 12 231 female [60.9%]), of whom 4211 (21.0%) had BL documented allergy and 15 881 (79.0%) did not, met the inclusion criteria. A total of 3513 patients (17.5%) were Black, 15 358 (76.4%) were White, and 1221 (6.0%) were another race. Using generalized estimating equations, documented BL allergies were not significantly associated with the odds of mortality (odds ratio [OR], 1.02; 95% CI, 0.96-1.09). BL allergies were associated with increased odds of MRSA infection (OR, 1.44; 95% CI, 1.36-1.53), VRE infection (OR, 1.18; 95% CI, 1.05-1.32), and the pooled rate of the 3 evaluated antibiotic-resistant infections (OR, 1.33; 95% CI, 1.30-1.36) but were not associated with C difficile infection (OR, 1.04; 95% CI, 0.94-1.16), stage 2 and 3 AKI (OR, 1.02; 95% CI, 0.96-1.10), or stage 3 AKI (OR, 1.06; 95% CI, 0.98-1.14). Conclusions and Relevance Documented BL allergies were not associated with the long-term odds of mortality but were associated with antibiotic-resistant infections. Health systems should emphasize accurate allergy documentation and reduce unnecessary BL avoidance.
Restored Cytokine-Producing Capacities of Mucosal-Associated Invariant T Cells in Pediatric Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor
Authors: Emmanuelle Bardin, Céline Dietrich, Messaouda Attailia, Agnès Ferroni, Anne Jamet, Guillaume Lezmi, Isabelle Sermet-Gaudelus, Maria Leite-de-Moraes
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Atypical Hemolytic Uremic Syndrome due to Factor H Antibodies Following COVID-19
Authors: Salman B. Mahmood, Nattawat Klomjit
Journal: Journal of the American Society of Nephrology (2022)

Journal of the American Society of Nephrology 33(11S):p 337, November 2022. | DOI: 10.1681/ASN.20223311S1337c
Hemoperfusion With Seraph-100 Is Not Associated With Improved Survival in Severe COVID-19 Patients
Authors: Maria Martinez, Paula Ardura, Mercedes Artola, Arturo Lorenzo, Arinson Vasquez, Amanda Francisco, Maria Isabel Acosta-Ochoa, Maria Bustamante, Pablo Gonzalez, Elena Bustamante, Armando Coca
Journal: Journal of the American Society of Nephrology (2022)

Martinez, Maria; Ardura, Paula; Artola, Mercedes; Lorenzo, Arturo; Vasquez, Arinson; Francisco, Amanda; Acosta-Ochoa, Maria Isabel; Bustamante, Maria; Gonzalez, Pablo; Bustamante, Elena; Coca, Armando Author Information
Association of Acute eGFR Changes With Mortality and Heart Failure Hospitalizations Among Patients Admitted for Acute Heart Failure Requiring Hemodynamic Monitoring
Authors: Run Banlengchit, Hocine Tighiouart, Jake Gillberg, Marcelle Tuttle, Jeffrey M. Testani, Tatsufumi Oka, Michael S. Kiernan, Mark J. Sarnak, Wendy I. McCallum
Journal: Journal of the American Society of Nephrology (2022)
A Rare Case of Granulomatous Interstitial Nephritis in a Patient With COVID-19-Associated Collapsing Glomerulopathy
Authors: Manal Alotaibi, Carla L. Ellis, Shikha Wadhwani, Yonatan A. Peleg
Journal: Journal of the American Society of Nephrology (2022)

Alotaibi, Manal; Ellis, Carla L.; Wadhwani, Shikha; Peleg, Yonatan A. Author Information
Preparing a Clinical Outcomes Assessment Set for Nephrotic Syndrome (Prepare-NS): A New Core Set of Clinical Outcome Assessments Focused on Fluid Overload for Nephrotic Syndrome
Authors: Eloise Salmon, Debbie Gipson, Noelle E. Carlozzi, Jin-Shei Lai, Patrick H. Nachman, David T. Selewski, Richard A. Lafayette, Kelly Helm, Cathie Spino, Courtney N. Hurt, Rebecca Scherr, Vivian Kurtz, Yujie Wang, Daniayl Shamim, John D. Peipert
Journal: Journal of the American Society of Nephrology (2022)
Increased Dopamine D1 Receptor (D1R) Phosphorylation due to G Protein-Coupled Receptor Kinase 4 (GRK4) Variant 65L Causes Hypertension
Authors: Shaun C. Moore, Daniel A. Yaqub, Laureano D. Asico, Ines Armando, Pedro A. Jose
Journal: Journal of the American Society of Nephrology (2022)

Moore, Shaun C.; Yaqub, Daniel A.; Asico, Laureano D.; Armando, Ines; Jose, Pedro A. Author Information
Outcomes Among Hospitalized Patients With COVID-19 and AKI: Role of SARS-CoV-2 Vaccine
Authors: Jose L. Torres Cuevas, Froylan D. Martinez-Sanchez, Hector R. Gonzalez Sanchez, Santiago Saenz-Ancira, Yatzil Reyna Juárez, Alejandra Diaz-Jarquin, Carlos A. Romero-Reyes, Luis A. Ibarra Santoyo, Joana B. Juarez, Mauricio A. Salinas-Ramirez, Erika K. Tenorio-Aguirre
Journal: Journal of the American Society of Nephrology (2022)

Torres Cuevas, Jose L.; Martinez-Sanchez, Froylan D.; Gonzalez Sanchez, Hector R.; Saenz-Ancira, Santiago; Juárez, Yatzil Reyna; Diaz-Jarquin, Alejandra; Romero-Reyes, Carlos A.; Ibarra Santoyo, Luis A.; Juarez, Joana B.; Salinas-Ramirez, Mauricio A.; Tenorio-Aguirre, Erika K. Author Information
A Novel Approach in a Case of Cryoglobulinemic Glomerulonephritis
Authors: Pooja Kalantri, Koba A. Lomashvili
Journal: Journal of the American Society of Nephrology (2022)

Journal of the American Society of Nephrology 33(11S):p 804, November 2022. | DOI: 10.1681/ASN.20223311S1804a
A Rare Case of IgG4-Related Kidney Disease With a Rapid Growing Renal Tumor After COVID-19 Vaccination
Authors: Rei Nakazato, Akiko Mii, Akira Shimizu
Journal: Journal of the American Society of Nephrology (2022)

Journal of the American Society of Nephrology 33(11S):p 335, November 2022. | DOI: 10.1681/ASN.20223311S1335b
IgA Vasculitis After COVID-19 Vaccination: A Rare but Significant Complication
Authors: Michael W. George, Kristen Tomaszewski, Sylvester Dorobisz, John R. Sedor
Journal: Journal of the American Society of Nephrology (2022)

George, Michael W.; Tomaszewski, Kristen; Dorobisz, Sylvester; Sedor, John R. Author Information
C3 Glomerulonephritis After Vector COVID-19 Vaccination: A Case Report
Authors: Akilandanayaki Angamuthu, Zahir Ali Shaikh, Imara Dissanayake, Manjula Balasubramanian, Saurabh Gupta
Journal: Journal of the American Society of Nephrology (2022)

Angamuthu, Akilandanayaki; Shaikh, Zahir Ali; Dissanayake, Imara; Balasubramanian, Manjula; Gupta, Saurabh Author Information
Low Chronicity Score at Kidney Biopsy Predicts Renal Recovery From Dialysis in Patients With ANCA-Associated Vasculitis With Glomerulonephritis
Authors: Dalia Zubidat, Marta I. Casal Moura, Marc Patricio-Liébana, Maria Jose Soler, Fernanda G. Dos Santos, Luca Nardelli, Juan C. León Román, Ciria L. De Sousa, Ladan Zand, Sanjeev Sethi, Ulrich Specks, Fernando C. Fervenza
Journal: Journal of the American Society of Nephrology (2022)
A Case of Lupus Podocytopathy in Transition to Membranous Lupus Nephritis Class V With Positive APOL-1 Gene
Authors: Venkata Kishore R. Mukku, Marjan Afrouzian, Tina Kochar
Journal: Journal of the American Society of Nephrology (2022)

Journal of the American Society of Nephrology 33(11S):p 805-806, November 2022. | DOI: 10.1681/ASN.20223311S1805d
Cardiac Radiation Exposure and Coronary Atherosclerosis: An Inflammatory Interplay
Authors: Prerna R. Nepali, Mickael Mathieu, Sebastien Monette, Yunping Qiu, Irwin J. Kurland, Andreas Rimner, Adriana Haimovitz-Friedman, Edgar A. Jaimes
Journal: Journal of the American Society of Nephrology (2022)
Association of Serum Ferritin and Hepcidin With Renal Recovery in Community Acquired AKI
Authors: Jasmine Sethi, Vivek Kumar, Ashok K. Yadav
Journal: Journal of the American Society of Nephrology (2022)

Journal of the American Society of Nephrology 33(11S):p 347, November 2022. | DOI: 10.1681/ASN.20223311S1347a
The Circadian Clock Protein PER1 Mediates Sex-Dependent Effects on Arterial Stiffness
Authors: Ravindra K. Sharma, Joshua Gomes, G. R. Crislip, Hannah M. Costello, Lauren G. Douma, Suraj Krishnan, Kityan Cheng, Rajesh Mohandas, Michelle L. Gumz
Journal: Journal of the American Society of Nephrology (2022)
Unmasking the C3ulprit
Authors: Audai Ma'ayah, Brian Benes, Kathleen Borghoff, Kirk W. Foster, Prasanth Ravipati
Journal: Journal of the American Society of Nephrology (2022)

Ma'ayah, Audai; Benes, Brian; Borghoff, Kathleen; Foster, Kirk W.; Ravipati, Prasanth Author Information
Kidney Outcomes in Critically Ill Patients With and Without COVID-19
Authors: Frances Tian, Leila R. Zelnick, Mark M. Wurfel, Pavan K. Bhatraju, Bryan R. Kestenbaum
Journal: Journal of the American Society of Nephrology (2022)

Tian, Frances; Zelnick, Leila R.; Wurfel, Mark M.; Bhatraju, Pavan K.; Kestenbaum, Bryan R. Author Information
Afferent Neurons of the Kidney With Impaired Firing Pattern in Inflammation: Role of Sodium and Potassium Currents
Authors: Kristina Rodionova, Roland Veelken, Karl F. Hilgers, Peter Linz, Christian Ott, Roland E. Schmieder, Mario Schiffer, Kerstin U. Amann, Tilmann Ditting
Journal: Journal of the American Society of Nephrology (2022)
COVID-19 Mortality in Kidney Transplant Recipients: Analysis of Risk Factors
Authors: Michael Turk, Laith Alhuneafat, Ali W. Rizvi, Naman Gupta, Katherine Barnett, Ramya Gutta, Shane Mealy, Tabeer Rana, Aaisha Shah, Alisha Sharma, Omar Osman, Kalathil K. Sureshkumar
Journal: Journal of the American Society of Nephrology (2022)

Turk, Michael; Alhuneafat, Laith; Rizvi, Ali W.; Gupta, Naman; Barnett, Katherine; Gutta, Ramya; Mealy, Shane; Rana, Tabeer; Shah, Aaisha; Sharma, Alisha; Osman, Omar; Sureshkumar, Kalathil K. Author Information
Reduced Dose Non-Cyclical Oral Cyclophosphamide and Prednisolone for Membranous Nephropathy
Authors: Karppagavalli Subramaniam, Srimathi Ponnusamy, Mangalakumar Veerasamy
Journal: Journal of the American Society of Nephrology (2022)

Subramaniam, Karppagavalli; Ponnusamy, Srimathi; Veerasamy, Mangalakumar Author Information
Serum Uromodulin as a Marker for AKI and Chronic Nephron Loss
Authors: Eva Vonbrunn, Nadja Ebert, Kerstin U. Amann, Christoph Daniel
Journal: Journal of the American Society of Nephrology (2022)

Journal of the American Society of Nephrology 33(11S):p 347-348, November 2022. | DOI: 10.1681/ASN.20223311S1347c
Ouabain as an Early Marker of AKI
Authors: Lorenzo Cocchini, Marta De Filippo, Matteo Marcello, Davide Raimondo, Chiara Lanzani, Elisabetta Messaggio, Lorena Citterio, Laura Zagato, Giuseppe Vezzoli, Paolo Manunta, Marco Simonini
Journal: Journal of the American Society of Nephrology (2022)
Efficacy and Safety of Remission Induction Regimens in Elderly Patients With ANCA-Associated Glomerulonephritis
Authors: Lillian Xu, Faten F. Aqeel, Yumeng Wen, Duvuru Geetha
Journal: Journal of the American Society of Nephrology (2022)

Journal of the American Society of Nephrology 33(11S):p 795, November 2022. | DOI: 10.1681/ASN.20223311S1795a